Evidence map›Paper›PMID 40067634›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Development of Novel Neuroprotective Agents Targeting GPCR Using in Vitro Assays.

María Gómez-Cañas, Carmen Rodríguez-Cueto, Javier Fernández-Ruiz, Eva de Lago

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

María Gómez-CañasInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Carmen Rodríguez-CuetoInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Javier Fernández-RuizInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
Eva de LagoInstituto Universitario de Investigación en Neuroquímica, Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, Madrid, Spain. elagofem@ucm.es.ORCID 0000-0002-6260-3777

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter aims to elucidate an example of the drug development process for a G protein-coupled receptor (GPCR), focusing specifically on the cannabinoid receptors CB

Indexed as

Drug DevelopmentNeuroprotective AgentsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, G-Protein-CoupledAnimalsCannabinoidsDrug DiscoveryHumansProtein BindingSignal TransductionCannabinoidsNeuroprotective AgentsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Receptors, G-Protein-CoupledCannabinoid receptorsCompetition binding assaysDrug discoveryGPCRsIn vitro functional activity determinationIn vitro neuroprotection assays

Identifiers

PMID40067634

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.